A Pilot Study to Evaluate Safety and Effectiveness of Lanreotide in the Treatment of Patients With Small Bowel Motility Disorders (SBMD): a Prospective, Non-randomized, Single-center Study of 20 Participants
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Lanreotide (Primary)
- Indications Gastrointestinal motility disorders
- Focus Therapeutic Use
- 05 Feb 2018 Planned end date changed from 1 Dec 2018 to 1 Apr 2019.
- 05 Feb 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2018.
- 09 Jan 2017 New trial record